$KZR
Kezar Life Sciences, Inc. Stock $kzr

$kzr Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000156459021043979 Filed on August 12, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.668M	$2.710M
YoY Change	35.35%	11.52%
% of Gross Profit
Research & Development	$9.341M	$7.148M
YoY Change	30.68%	3.22%
% of Gross Profit
Depreciation & Amortization	$300.0K	$300.0K
YoY Change	0.0%	50.0%
% of Gross Profit
Operating Expenses	$13.01M	$9.853M
YoY Change	32.03%	5.32%
Operating Profit	-$13.01M	-$9.853M
YoY Change	32.03%	5.32%
Interest Expense	$0.00	$353.0K
YoY Change	-100.0%	-44.58%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.96M	-$9.500M
YoY Change	36.44%	8.94%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.96M	-$9.500M
YoY Change	36.44%	8.97%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.25
Diluted Earnings Per Share	-$0.25	-$221.2K
COMMON SHARES
Basic Shares Outstanding	51.90M
Diluted Shares Outstanding	51.90M	42.94M

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$129.0M	$157.5M
YoY Change	-18.11%	68.63%
Cash & Equivalents	$26.38M	$17.30M
Short-Term Investments	$102.6M	$140.2M
Other Short-Term Assets	$4.371M	$1.312M
YoY Change	233.16%	13.1%
Inventory
Prepaid Expenses		$1.780M
Receivables
Other Receivables
Total Short-Term Assets	$133.3M	$160.6M
YoY Change	-16.95%	66.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.017M	$3.902M
YoY Change	-22.68%	-17.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$282.0K	$282.0K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$6.326M	$7.760M
YoY Change	-18.48%	-14.07%
TOTAL ASSETS
Total Short-Term Assets	$133.3M	$160.6M
Total Long-Term Assets	$6.326M	$7.760M
Total Assets	$139.7M	$168.3M
YoY Change	-17.02%	59.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.633M	$1.007M
YoY Change	62.16%	5.45%
Accrued Expenses	$3.186M	$3.027M
YoY Change	5.25%	5.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.944M	$5.045M
YoY Change	17.82%	6.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.842M	$5.000M
YoY Change	-23.16%	-15.25%
Total Long-Term Liabilities	$3.842M	$5.000M
YoY Change	-23.16%	-15.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.944M	$5.045M
Total Long-Term Liabilities	$3.842M	$5.000M
Total Liabilities	$9.786M	$10.01M
YoY Change	-2.19%	-6.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.0M	-$103.8M
YoY Change	46.44%	58.34%
Common Stock		$262.1M
YoY Change		63.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$129.9M	$158.3M
YoY Change
Total Liabilities & Shareholders Equity	$139.7M	$168.3M
YoY Change	-17.02%	59.9%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$12.96M	-$9.500M
YoY Change	36.44%	8.97%
Depreciation, Depletion And Amortization	$300.0K	$300.0K
YoY Change	0.0%	50.0%
Cash From Operating Activities	-$13.04M	-$10.09M
YoY Change	29.26%	30.87%
INVESTING ACTIVITIES
Capital Expenditures	-$24.00K	-$20.00K
YoY Change	20.0%	-95.92%
Acquisitions
YoY Change
Other Investing Activities	$16.28M	-$37.26M
YoY Change	-143.68%	-1516.73%
Cash From Investing Activities	$16.25M	-$37.28M
YoY Change	-143.6%	-1842.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	277.0K	43.99M
YoY Change	-99.37%	24338.89%
NET CHANGE
Cash From Operating Activities	-13.04M	-10.09M
Cash From Investing Activities	16.25M	-37.28M
Cash From Financing Activities	277.0K	43.99M
Net Change In Cash	3.488M	-3.380M
YoY Change	-203.2%	-37.29%
FREE CASH FLOW
Cash From Operating Activities	-$13.04M	-$10.09M
Capital Expenditures	-$24.00K	-$20.00K
Free Cash Flow	-$13.02M	-$10.07M
YoY Change	29.28%	39.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M24D
	kzr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm	P6Y6M
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.871
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.881
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.871
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.838
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.877
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.908
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.881
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.908
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.010
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.005
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.011
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.005
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.011
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.016
CY2021Q2	kzr	Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	282000
CY2021Q2	kzr	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises	7000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1937000
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-15000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12962000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	129886000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	78046000
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3447000
CY2020Q1	kzr	Stock And Pre Funded Warrants Issued During Period Net Of Offering Costs Value StockAndPreFundedWarrantsIssuedDuringPeriodNetOfOfferingCostsValue	53360000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3087000
CY2020Q2	kzr	Stock And Pre Funded Warrants Issued During Period Net Of Offering Costs Value StockAndPreFundedWarrantsIssuedDuringPeriodNetOfOfferingCostsValue	43663000
CY2020Q2	kzr	Value Of Issuance Of Shares Under Incentive And Share Based Compensation Plans ValueOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	125000
CY2020Q2	kzr	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Related To Shares Of Common Stock Issued Pursuant To Early Exercises AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingRelatedToSharesOfCommonStockIssuedPursuantToEarlyExercises	10000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1219000
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	147000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9500000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	158318000
	us-gaap	Profit Loss ProfitLoss	-25956000
	us-gaap	Profit Loss ProfitLoss	-19512000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	745000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	731000
	us-gaap	Share Based Compensation ShareBasedCompensation	3865000
	us-gaap	Share Based Compensation ShareBasedCompensation	2392000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1045000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	183000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	166000
	kzr	Increase Decrease Accounts Payable Accrued Liabilities And Other Current Liabilities IncreaseDecreaseAccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilities	-576000
	kzr	Increase Decrease Accounts Payable Accrued Liabilities And Other Current Liabilities IncreaseDecreaseAccountsPayableAccruedLiabilitiesAndOtherCurrentLiabilities	-1219000
	us-gaap	Operating Lease Payments OperatingLeasePayments	504000
	us-gaap	Operating Lease Payments OperatingLeasePayments	435000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21402000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18392000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	110000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	37913000
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	143780000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	53500000
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	67284000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15563000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-76606000
	kzr	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	10673000
	kzr	Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts	97235000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	344000
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	128000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11017000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	97363000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24000
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-20000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5154000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2345000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21228000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14951000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26382000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17296000
	kzr	Reclassification Of Employee Stock Liability To Equity Upon Vesting ReclassificationOfEmployeeStockLiabilityToEquityUponVesting	14000
	kzr	Reclassification Of Employee Stock Liability To Equity Upon Vesting ReclassificationOfEmployeeStockLiabilityToEquityUponVesting	20000
	kzr	Unpaid Offering Costs In Accrued Liabilities UnpaidOfferingCostsInAccruedLiabilities	25000
	kzr	Unpaid Offering Costs In Accrued Liabilities UnpaidOfferingCostsInAccruedLiabilities	212000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152000000.0
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	7013000
CY2021Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1000
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	6000
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0
CY2021Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	126451000
CY2021Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	126466000
CY2021Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	126451000
CY2021Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	126466000
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6217000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6177000
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3200000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2742000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3017000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3435000
CY2021Q2	us-gaap	Depreciation Depreciation	300000
	us-gaap	Depreciation Depreciation	500000
CY2020Q2	us-gaap	Depreciation Depreciation	300000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37902294
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7314814
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7314814
CY2021Q2	kzr	Accrued Preclinical And Research Costs Current AccruedPreclinicalAndResearchCostsCurrent	962000
CY2020Q4	kzr	Accrued Preclinical And Research Costs Current AccruedPreclinicalAndResearchCostsCurrent	461000
CY2021Q2	kzr	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	989000
CY2020Q4	kzr	Accrued Clinical Costs Current AccruedClinicalCostsCurrent	929000
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	931000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1355000
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	202000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	103000
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	102000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	173000
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3186000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3021000
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	259000
	us-gaap	Operating Lease Payments OperatingLeasePayments	504000
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	275000
	us-gaap	Operating Lease Cost OperatingLeaseCost	550000
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	180000
	us-gaap	Variable Lease Cost VariableLeaseCost	374000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	775000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1588000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1635000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1684000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	282000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5964000
CY2021Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1004000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4960000
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1118000
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3842000
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4960000
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2884615
CY2020Q1	kzr	Warrant Issue Price Per Share WarrantIssuePricePerShare	2.599
CY2020Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	909091
CY2020Q2	kzr	Warrant Issue Price Per Share WarrantIssuePricePerShare	5.499
CY2021Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2021Q2	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P20Y
CY2021Q2	kzr	Maximum Ownership Percentage Of Holders Upon Exercise Of Warrants MaximumOwnershipPercentageOfHoldersUponExerciseOfWarrants	0.0499
CY2021Q2	kzr	Maximum Ownership Percentage Allowed To Be Increased Or Decreased By Warrant Holders Upon Prior Notice MaximumOwnershipPercentageAllowedToBeIncreasedOrDecreasedByWarrantHoldersUponPriorNotice	0.1999
CY2021Q2	kzr	Class Of Warrants Or Rights Exercised ClassOfWarrantsOrRightsExercised	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	3793706
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4489122
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.14
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7134000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3192000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.49
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	24543
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.24
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	66000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	344717
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.21
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7311862
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.86
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7395000
CY2021Q2	kzr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	3175152
CY2021Q2	kzr	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableWeightedAverageExercisePrice	5.79
CY2021Q2	kzr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Exercisable Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableIntrinsicValue	5617000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1937000
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1219000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3865000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2392000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2015Q4	kzr	Research And Development Tax Credit Maximum Utilization Against Employers Portion Of Payroll Tax ResearchAndDevelopmentTaxCreditMaximumUtilizationAgainstEmployersPortionOfPayrollTax	250000
CY2021Q2	kzr	Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses	0
	kzr	Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses	154000
CY2020Q2	kzr	Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses	108000
	kzr	Research And Development Tax Credit Utilized As Reduction Of Payroll Expenses ResearchAndDevelopmentTaxCreditUtilizedAsReductionOfPayrollExpenses	264000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12962000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-9500000
	us-gaap	Net Income Loss NetIncomeLoss	-25956000
	us-gaap	Net Income Loss NetIncomeLoss	-19512000
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51904701
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42936991
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51483709
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.51
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4497483
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4497483

Files In Submission

Name	View Source	Status
R41.htm	Edgar Link	pending
0001564590-21-043979-index-headers.html	Edgar Link	pending
0001564590-21-043979-index.html	Edgar Link	pending
0001564590-21-043979.txt	Edgar Link	pending
0001564590-21-043979-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmrpuoelzf2z000001.jpg	Edgar Link	pending
kzr-10q_20210630.htm	Edgar Link	pending
kzr-10q_20210630_htm.xml	Edgar Link	completed
kzr-20210630.xsd	Edgar Link	pending
kzr-20210630_cal.xml	Edgar Link	unprocessable
kzr-20210630_def.xml	Edgar Link	unprocessable
kzr-20210630_lab.xml	Edgar Link	unprocessable
kzr-20210630_pre.xml	Edgar Link	unprocessable
kzr-ex311_7.htm	Edgar Link	pending
kzr-ex312_6.htm	Edgar Link	pending
kzr-ex321_8.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KZR
Kezar Life Sciences, Inc. Stock $kzr

2021 Q2 Form 10-Q Financial Statement

#000156459021043979 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KZR Kezar Life Sciences, Inc. Stock $kzr

2021 Q2 Form 10-Q Financial Statement

#000156459021043979 Filed on August 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KZR
Kezar Life Sciences, Inc. Stock $kzr